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ABSTRACT
RYAN TYLER JOHNSON: The Creation and Characterization of Vaccines Expressing
the Premembrane and Glycoprotein E Antigens of the West Nile Virus
(Under the direction of Dr. Wayne Gray)
The West Nile Virus (WNV) is a positive polarity, single-stranded RNA virus
belonging to the family Flaviviridae. In this family, there are several globally relevant
human pathogens including dengue fever virus (DENV), Japanese encephalitis virus
(JEV), yellow fever virus (YFV), the newly emerging Zika virus, and the West Nile
Virus (WNV). WNV, like other Flaviviruses, is spread by an arthropod vector, and can
cause West Nile fever and West Nile encephalitis and meningitis, and is now considered
to be endemic in Africa, Asia, Europe, the Middle East, and the United States. No
vaccine is currently available to prevent WNV infection, and it is clear that one is needed.
This thesis aims to provide significant, relevant background information,
pathophysiology, epidemiology, and highlight various vaccination strategies that have
been attempted or are currently being researched to combat WNV. Furthermore, this
paper aims to provide a plausible solution to WNV with two different vaccines that were
created: a DNA and recombinant Varicella Zoster Virus (rVZV) vaccine, both expressing
the pre-membrane and glycoprotein E antigens of the virus. The DNA vaccine achieved
successful transfection and expression in Vero cells.
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INTRODUCTION
In this study, the area of focus is the creation of two possible modes of
vaccination for the West Nile Virus (WNV), which plagues many parts of the world and
is now endemic in both hemispheres. The WNV is a positive, single-stranded RNA
Flavivirus. Like other flaviviruses, the WNV is spread by means of an arthropod vector,
with birds being the reservoir hosts, humans being the dead-end host, and mosquitos
being the vector that ensures the cycle of infection.
The types of vaccines that were created and that will be discussed in this paper are
a DNA vaccine and a recombinant Varicella Zoster Virus (rVZV) vaccine. Both vaccine
types will be expressing the Pre-membrane (prM) and the glycoprotein E (gE) antigens of
the WNV. Both antigens are structural proteins that are vital to the virus’s formation and
successful infection into the host cell. The DNA vaccine is a relatively new vaccine
construct that has been proven to be safe, reliable, and cost-effective. It involves inserting
the antigens of a disease into a vector, which gives protection to the individual without
the injection of infectious agents like traditional vaccine methods. The rVZV vaccine is a
relatively new construct that some researchers are starting to work with in the field of
virology. The VZV vaccine has seen large scale success since its inception and has been
proven to be safe and effective. The vaccine genome is large enough to insert genes of
interest and still be effectively transfected. The aim of this paper is to create and
characterize these vaccine types in the hope that one day a safe and effective vaccine for
the WNV will be created, approved, and used on a large scale.
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CHAPTER I: WNV BACKGROUND INFORMATION, CLINCAL USE,
PATHOPHYSIOLOGY, EPIDEMIOLOGY, AND VACCINATION STRATEGIES

INTRODUCTION
West Nile Virus (WNV) is an RNA virus that is a member of the Japanese
encephalitis antigenic complex of the family Flaviviridae. It is commonly found in
Africa, Europe, the Middle East, North America, and West Asia. (1) Like other
flaviviruses, it is spread by means of an arthropod vector. In nature, it is maintained in a
cycle involving transmission between mosquitoes and birds, with birds being the
reservoir hosts and mosquitoes being the vector of infection. Humans are referred to as
the “dead-end hosts”, because while they can become infected, they cannot transmit the
virus any further. WNV was first isolated in a woman in the West Nile district of Uganda
in 1937, earning it its name. In 1999, it was reported in New York which produced a
large outbreak that spread throughout the United States in the following years. Outbreak
sites are observed to occur on major bird migratory routes.
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MOLECULAR PROPERTIES OF WNV:

Figure 1 - WNV Structure

The structure of the West Nile virus is vital knowledge to understand how the
virus operates and conveys infection in an individual (Figure 1). The outer layer of the
virus is composed of a lipid bilayer and serves as the envelope of the virus. The presence
of an envelope tells us that the virus is unstable in the external environment, which is
why it requires a vector to successfully transmit to a host. The spikey protrusions seen on
the surface of the virus are the glycoproteins that project out from the envelope, which
helps the virus bind to the host cells. Tucked away safely in the center of the virus is the
nucleocapsid, which is composed of two main parts: the capsid, which is the icosahedralshaped protein shell that protects the genetic information on the inside, and the RNA, the
single-stranded genetic information of the virus. (21)
The WNV proteins of interest in this study are the Pre-membrane and
glycoprotein E (PrMgE) antigens. The pre-membrane protein of flaviviruses is a
structural protein, and it plays an important role of conformational folding of the
envelope protein of the virus and helps protect it against pre-mature fusion in the acidic
vesicles of the Golgi network (3). Glycoprotein E is the major envelope protein of the
WNV and is necessary for viral entry into the membrane of a cell. The protein undergoes
3

a conformational rearrangement triggered by low pH that results in a class II fusion
event, which is required for viral entry. (4) In this study, we believe that successful
integration of these antigens of interest into a vaccine will provide ample immunological
protection against the WNV by ensuring that the virus is identified and eliminated by the
host immune response before the virus is allowed to gain access to host cells in order to
replicate.

CLINICAL ASPECTS:
The incubation period of the virus is typically 3 to 14 days. WNV infection is
asymptomatic in approximately 80% of individuals but can lead to West Nile Fever in
roughly 20% of afflicted persons, with about 1 in 150 persons developing severe
neurological diseases associated with the virus. (2) The severe diseases that can occur
include various neuroinvasive diseases such as West Nile encephalitis or meningitis, and
the symptoms include headache, high fever, neck stiffness, stupor, disorientation, coma,
tremors, convulsions, muscle weakness, paralysis, and sometimes death. These serious
illnesses can occur at any age, although people over the age of 50 and
immunocompromised patients, such as those who have undergone transplant surgeries or
have HIV, are at the most risk for developing the serious forms of the disease. Diagnosis
of WNV can be determined by a number of different tests, including IgG antibody seroconversion by ELISA analysis, neutralization assays, viral detection by RT-PCR assay,
and virus isolation by cell culture. Treatment for WNV severe symptoms include
hospitalization, IV fluids, respiratory support, and prevention of secondary infections.
There is no vaccine available for humans. The main defense against the virus lies in
preventive measures, such as raising awareness of the risks associated with exposure to
4

the virus. Vector control has also shown to be effective, such as careful monitoring and
control of mosquito populations in areas where the virus is common.

PATHOPHYSIOLOGY OF WNV:
Rodent models have provided much valuable insight into the mechanisms of
WNV dissemination and pathogenesis. (5) Following the initial skin perforation, the
initial replication of the WNV is theorized to occur in skin Langerhans dendritic cells.
The infected cells then travel to and seed draining lymph nodes, resulting in a primary
viremia and subsequent infection of peripheral tissues such as the spleen and kidney.
Most of the time, WNV is largely cleared from the serum and other peripheral organs
after the first week, with the immunocompromised and elderly immune systems being the
subset that experiences the secondary infections. Persistent infection and viremia have
been detected in immunosuppressed patients for more than 60 days. The way that WNV
crosses the blood brain barrier remains largely unknown, but there are many theories that
have supporting evidence. It is known that tumor necrosis factor-α mediates changes in
the endothelial cell permeability of the blood brain barrier (BBB), and this is a possible
facilitation method that allows WNV access to the CNS. Additional mechanisms may
contribute to WNV CNS infection, including (i) infection or passive transport through the
endothelium or choroid plexus epithelial cells (6), (ii) infection of olfactory neurons and
spread to the olfactory bulb (7) (iii) a “Trojan horse” mechanism in which the virus is
transported by infected immune cells that traffic to the CNS (8), and (iv) direct axonal
retrograde transport from infected peripheral neurons (9). Although the precise
mechanisms of WNV CNS entry in humans require additional study, changes in cytokine
levels that may modulate BBB permeability and infection of blood monocytes and
5

choroid plexus cells have been documented in animal models. Experiments with smallanimal models have demonstrated that T Lymphocytes are essential to protection against
WNV. (10) As expected, individuals with hematologic malignancies and impaired T-cell
function have an increased risk of neuroinvasive WNV infection. Upon recognition of a
WNV-infected cell that expresses class I MHC molecules, antigen-restricted cytotoxic T
lymphocytes proliferate, release pro-inflammatory cytokines, and lyse cells directly
through the delivery of perforin and granzymes A and B or via Fas-Fas ligand
interactions. Although there is a lot to be learned about the defined immunity process
against WNV, both humoral and cellular responses are likely necessary for protection
against the virus. Specific neutralizing antibodies are generated at late times after primary
WNV infection, and the development of high-titer neutralizing antibodies after
vaccination directly correlates with the typical antibody levels after a challenge with the
virus. (11, 12). Some authors also suggest that cell adhesion molecules may help to traffic
West Nile virus-infected immune cells into the central nervous system. (13).

EPIDEMIOLOGY OF WNV
WNV is one of the most widely distributed of all arboviruses with an extensive
distribution among both hemispheres of the world. Many consider the origin of WNV to
be North Africa, although the virus is now considered endemic in several places
including Europe, South America, and even North America. (14) Since the discovery of
WNV, infrequent human outbreaks were most commonly reported in groups of children,
soldiers, and healthy adults in Israel and Africa. These outbreaks resulted in only minor
illness in the majority of patients, and the few deaths that occurred were mainly
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associated with old age. Since the mid-90s, however, severe virus infection associated
with encephalitis have occurred in North Africa, Tunisia, Sudan, Europe, Russia, Israel,
North America, Canada, and India. Among these, the mortality associated with the virus
was at approximately 10% and occurred mainly in elderly patients. (14) There are no
known predispositions to infection by WNV due to race or sex.

VACCINATION METHODS:
There currently is no vaccine for WNV, although some have been attempted and
are awaiting further trials, mostly in animal models. A recombinant influenza virus
expressing Domain III (DIII) of the WNV E protein has been identified as a vaccine
candidate in models of mice. The WNV DIII was cloned into the N-terminal region of the
influenza virus, rendering the functional activity of the influenza protein inactive. This
study has found results of high IgG antibody ELISA titers through a subcutaneous
injection of the vaccine in mice. (22) Schepp-Berglind et al. created and characterized an
adenoviral vaccine vector (CAdVAX-WNVII) which expressed four WNV proteins: C,
prM, E, and NSI. Serum samples from mice that were administered this vaccine showed
antibodies that neutralized lineage I and II viruses, and increased T-cell activity against
WNV antigens were observed in vitro. (23) The main purpose of this study was to create
a DNA vaccine and recombinant VZV (rVZV) vaccine expressing the PrM and gE
antigens of the WNV.
DNA vaccination is a popular and proven method of vaccination against various
diseases. It is accomplished by injecting cells with genetically engineering DNA so that
the cells directly produce an antigen of that disease, producing a protective
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immunological response from one’s body. For many years, general vaccination has been
accomplished by either directly introducing antigens that are characteristic of the virus, or
by injecting a live, attenuated virus into the individual in order to prime their immune
system. The DNA vaccine offers many different advantages over traditional vaccination
methods. For example, DNA vaccines stimulate both the T- and B-cell responses,
improved vaccine stability. It also is able to accomplish these things with the absence of
infectious agents. Plus, they are relatively cheap and easy to mass produce. (15) The field
of DNA vaccination is fast growing, with many vaccines already in use and many more
currently in clinical trials. DNA vaccination is one of the methods which was researched
and applied in this experiment, and it was done by inserting the Pre-membrane and
glycoprotein E genes of the West Nile Virus into the vaccine vector pVAX1.
Another type of vaccination strategy that was utilized in the research conducted is
the recombinant Varicella Zoster Virus (rVZV) vaccine, which also had the Premembrane and glycoprotein E antigens inserted into it. VZV is a virus which can result in
chickenpox, primarily in younger patients, and can also reside as a dormant virus and
later manifest into the shingles disease in older adults. This virus infection has been
successfully prevented by the highly effective VZV vaccine that is readily available.
Several researchers, including Dr. Wayne Gray, have studied this vaccine construct
extensively and believe that it can be utilized in several other vaccination methods, such
as HIV and several other viruses in the flavivirus family (16). He, among other
researchers, cite the vaccine’s safety and effectiveness, claiming it provides support for
recombinant VZV (rVZV) vaccines to induce immunity against not only VZV but also
against other pathogens. The ability of VZV vaccines to safely induce long-lasting
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humoral and cellular immune responses provides advantages over other live, attenuated
vaccine vectors and over killed and subunit vaccines. (16) There are also several other
reasons that the vaccine can offer these advantages, such as the size of the vaccine
(125kb) allows the stable insertion of several heterologous genes into specific loci
without hindering viral replication. (17) Also, VZV replicates in the cell nucleus, which
gives the opportunity for foreign, inserted genes to be spliced and replicated as is done in
natural viral replication. (18) The host range of VZV is also limited to humans,
eliminating the possibility of uncontrollable environmental spread. In addition, periodic
subclinical reactivation of VZV from latency may provide re-stimulation of immune
responses to VZV and foreign antigens (19). Experiments performed by Dr. Gray and his
colleagues have shown promise in utilizing the rVZV vaccine to guard against SIV and
other flaviviruses, including Dengue Fever and the re-emerging Zika Virus. The goal of
this experiment is to create and characterize a rVZV vaccine that has the potential to
induce an immune response to the WNV antigens discussed above.

9

CHAPTER II: DNA VACCINE CONSTRUCTION & TRANSFECTION

INTRODUCTION
DNA vaccines are a type of nucleic acid vaccine that is a relatively new and fastgrowing discipline in the world of vaccines. They are accomplished by inserting various
antigens of the disease inside of a vaccine construct, which then stimulates the immune
system response. There are many advantages to using a DNA vaccine. They have been
proven to be very safe, since no infectious agent is actually introduced to the body, such
as the case with traditional vaccination methods which use live, attenuated viruses or
killed viruses. They are also very easy to mass produce, relatively cheap to make, and
have proven in some studies to be more stable than other vaccination strategies (15).
DNA vaccines also stimulate both the T-cell and B-cell responses, activating both the
cell-mediated and humoral immune response. Priming the immune system in both ways
is key to successful protection against the infectious agents.
As effective as DNA vaccines can be, there are also disadvantages to be
addressed, with several limiting factors to the potential wide-spread use of DNA
vaccines. For one, this type of vaccination would be limited to pathogens that possess a
distinct protein immunogen (molecules that directly trigger an immune response). There
also is some speculation that introducing the foreign DNA into the body could have some
kind of effect on a cell's normal protein expressing pathways, although this has yet to be
shown as a major area of concern.
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SPECIFIC AIM OF THIS STUDY:
The DNA vaccine vector used in this study is the pVAX1 vector (Thermo-Fisher
Scientific) (Figure 2), which is Kanamycin resistant and is designed specifically for the
construction of DNA vaccines due to the size of the vector and the availability of unique
cloning sites in the MCS. The type of restriction site that is important in this study are the
BamH1 sites, which is where the WNVprMgE gene will be inserted once they are
digested (Figure 3). The gene of interest (WNVprMgE) will be inserted where the 5’
primer end is downstream of the CMV promotor region of the pVAX1 plasmid (Figure
4). After the vaccine is created, successful expression of the gene of interest will be
analyzed via PCR and further demonstrated through immunofluorescence of transfected
Vero cells.

Figure 2 – pVAX1 structure
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Figure 3 - Generic Plasmid Map

PROJECT OVERVIEW:
MCS

Figure 4 – Overview of DNA Vaccine Creation
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In this study, we isolated the WNVprMgE gene from the pucIDT vector, cloned it
into the pVAX1 vector, and then transfected the recombinant DNA into Vero cells to see
if the WNVprMgE antigens would be expressed in the cells (Figure 4). The first obstacle
that had to be overcome in the creation of this DNA vaccine was to separate the gene of
interest, in this case the WNVprMgE, from its original vector, the pucIDT vector, so that
it could be cloned into the new vaccine construct. The pucIDT vector contains BamH1
restriction sites where the genome can be cut with the restriction enzyme BamH1 during
a digest, thus separating the WNVprMgE gene so that it could be cut out, isolated, and
ligated into the new vector. The pVAX1 vector is the DNA vaccine into which the
WNVprMgE gene was cloned. It also contains BamH1 restriction sites in the Multiple
Cloning Site (MCS), which were digested using BamH1 to allow the insertion of the
WNVprMgE. The MCS is a region commonly found in many engineered plasmids that
can contain up to 20 different restriction sites, allowing diverse options for inserting
various genes. Afterwards, a T4 DNA ligation protocol was followed in order to clone the
WNVprMgE into the MCS region of the pVAX1 vector. Correct orientation of the
cloned-in WNVprMgE was analyzed with PCR using forward and reverse primers to
ensure that the WNV gene was inserted so that the ATG start codon is downstream of the
CMV promotor of the pVAX1 plasmid, and sequencing results confirmed correct
orientation (Eurofins Genomics). After the vaccine was created, the DNA was isolated
and transfected into Vero cells, and expression of the WNV antigens in the Vero cells
was confirmed with an immunofluorescence assay utilizing primary and secondary
antibodies (Invitrogen). The primary antibody was a mouse anti-WNVprMgE, which
means it will bind to the cells expressing the WNV antigens with the Fab end. The
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secondary antibody was goat anti-mouse IgG-FITC, meaning they will bind to the to the
Fc end of the primary antibodies. The secondary antibody was also fitted with a FITC
fluorescent marker on their FC end, which makes them visible under a fluorescent
microscope.

METHODS:

Midiprep DNA Extraction of pucIDT WNVprMgE from E. Coli (JM109)
E. Coli containing the pucIDT-WNVprMgE was grown overnight at 37 degrees in 5ml of
Luric Broth (LB) + Ampicillin (Amp). The 5ml culture of pucIDT WNVprMgE was then
transferred into 100ml of LB + Amp, which was incubated overnight at 37 degrees C.
The DNA was extracted using a Qiagen Plasmid Midi Kit and precipitated overnight at 4
degrees C in isopropanol (IPA). The DNA was then spun down in a centrifuge, washed,
and eluted into 50 μl of TE for storage. 5 μl of DNA was combined with 10 μl of loading
dye, and this was run on a 0.5% agarose + Ethidium Bromide (EtBr) gel.

Restriction Digest and Gel Purification of WNVprMgE and pVAX1 with BamH1:
20 μl of 59.9 ng/μl WNVprMgE and 20 μl of 60.2 ng/μl pVAX1 was cut overnight using
BamH1 and incubated in a water bath at 37 degrees C. The digests were set up as
follows: pVAX1 vector: 20 μl of DNA, 1 μl of d2H2O, 1.5 μl of BamH1, 2.5 μl of 10X
Buffer. WNVprMgE insert: 6 μl of DNA, 15 μl of d2H2O, 1.5 μl of BamH1, and 2.5 μl
of 10X Buffer. One μl of Shrimp Alkaline Phosphatase (rSAP) was added to the pVAX1
vector in order to prevent re-ligation to itself and incubated for 1 hour at 37 degrees C in
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a water bath. After the digest, the rSAP was heat-inactivated by incubation in a water
bath at 65 degrees C for approximately 10 minutes. The digests were run on a 0.5%
agarose + EtBr gel and gel-purified via a Quiagen Gel Extraction Kit, and the DNA was
eluted into 30 μl of TE. The purified and digested DNAs were run on a 0.5% agarose +
EtBr gel at 100V for 45 minutes for confirmation purposes. They were loaded into the gel
wells as follows: WNVprMgE insert: 5 μl of sample DNA and 5 μl of loading dye.
pVAX1 vector: 5 μl of sample DNA and 5 μl of loading dye.

T4 DNA Ligation of pVAX-1 & WNVprMgE and Transformation:
A T4 DNA ligase reaction was set up as follows: 4 μl of pVAX-1 gel-purified DNA, 4 μl
of WNVprMgE gel-purified DNA, 2 μl of Buffer 10X T4 Ligase buffer, and 1 μl of T4
Ligase. This reaction was incubated at room temperature for 1 hour. The ligase was
incubated for 10 minutes in a water bath at 65 degrees C. The pVAX1-WNVprMgE
DNA was electroporated into electro-competent NEB5-α cells using a 0.2 cm cuvet at 2.5
kilovolts. The pVAX1-WNVprMgE was then pipetted into 1ml of SOC media and the
cells were then allowed to recover for an hour at 37 degrees C. The cells were plated on
LB-Kanamycin plates and incubated overnight at 37 degrees C to grow clones. Clones
from the plates were randomly picked onto fresh LB-Kan. plates and incubated over the
weekend at 37 degrees C.
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PCR of pVAX1-WNVprMgE:
Miniprep DNA isolations were performed for the selected clones. A PCR was set up as
follows: 5 μl of DNA pVAX1-WNVprMgE NEB5-α, 1 μl of forward WNVprMgE
extension primer, 1 μl of reverse WNVprMgE primer, 43 μl of PCR Super-mix, for a
total of a 50-μl reaction. The PCR reaction was carried out as follows: (30x) 2-minute
initial denature at 94 degrees C, 45 second denature at 94 degrees C, 1 minute anneal at
55 degrees C, and a 2-minute elongation at 72 degrees C. This was followed by a 7minute final elongation at 72 degrees C and indefinite incubation at 4 degrees C. The
primers used were: Forward WNVprMgE = GCCACCATGGGAGGAAGACC. Reverse
WNVprMgE = CTATTAAGCGTGCACGTTCACGG (reverse compliment). The PCR
product was run on a 0.5% Agarose + EtBr gel for 60 minutes at 100V. The gel wells
were loaded as follows: well 1 (MW) = 3 μl of DNA Ladder and 5 μl of loading dye.
Well 2 (PCR product): 10 μl of DNA and 5 μl of loading dye.

DNA Extraction and BamH1 digest of pVAX1-WNVprMgE:
Six clones were selected at random and inoculated into a 5ml culture tube of LB and 10
μl of Kanamycin (clones 5-10), where they were incubated overnight at 37 degrees C.
DNA was extracted from the clones using the Qiagen Mini-Prep kit for confirmation of
pVAX1 and WNVprMgE DNA. The DNA was eluted into 50 μl of TE. A digest reaction
was set up for 3 hours at 37 degrees C as follows: 5 μl of DNA, 16 μl of d2H2O, 1.5 μl of
BamH1, and 2.5 μl of Buffer 10X. The digested product was then run on a 0.5% Agarose
+ EtBr gel at 100V for 45 minutes and analyzed.
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PCR confirmation of pVAX1-WNVprMgE clones 5-8:
A PCR was set up for each of the pVAX1-WNVprMgE NEB5-α positive clones (5, 6, 7,
and 8) as follows: 5 μl of clone DNA, 1 μl of reverse WNV-prMgE primer, 1 μl of T7
promoter, and 43 μl of PCR Super Mix. The PCR parameters were as follows: (30x) 2
minutes initial denature at 94 degrees C, 45 second denature at 94 degrees C, 1 minute
anneal at 55 degrees C, 3-minute elongation at 72 degrees C. A final elongation occurs at
72 degrees C for 7 minutes, followed by indefinite incubation at 4 degrees C. The PCR
products (clones 5, 6, 7, and 8) were then run on a 0.5% Agarose + EtBr gel for 45
minutes at 100V for confirmation as follows: well #1 – 3 μl DNA Ladder and 5 μl
loading dye. Wells #2-5 – 10 μl of PCA product and 5 μl of loading dye. (Figure 9)

Midiprep DNA Extraction of pVAX1-WNVprMgE NEB5-α (clone 5):
Five ml of LB broth and 10 μl of Kanamycin were inoculated with a positive clone of
pVAX1-WNVprMgE NEB5-α and was allowed to incubate overnight in a culture tube at
37 degrees C. This culture was then combined with a beaker containing 100ml of LB
broth and 200 μl of Kanamycin. This beaker was allowed to shake and incubate overnight
at 37 degrees C. The DNA was extracted using a Quiagen Plasmid Midi Kit (25) and was
eluted into 100 μl of EB Buffer and stored.

BamH1 Digest of pVAX1-WNVprMgE NEB5-α (clone 5):
A digest of the positive pVAX1-WNVprMgE NEB5-α clone was set up as follows: 1.5 μl
of BamH1, 2.5 μl of Buffer 10X, 2 μl of DNA, and 19 μl of d2H2O for a total reaction of
25 μl. This digest was allowed to incubate overnight in a water bath @ 37 degrees C. The
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digested DNA was then run and analyzed on a 0.5% Agarose +EtBr gel at 100V for 45
minutes.

Transfection of Vero Cells with pVAX1-WNVprMgE
The Vero cells were seeded onto culture chamber slides with a 10^5 + 2x10^5 per
chamber. The Lipofectamine 3000 Reagent (0.5 + 1.0 μl) was diluted in Opti-MEM
Medium (2 x 30 μl) and mixed. The Master Mix was prepared as follows: dilute 0.5 ng
DNA in 60 μl of Opti-MEM medium and 1 μl of P3000 was added and mixed well. 30 μl
of the diluted DNA was added to each tube of diluted Lipofectamine 3000 Reagent (1:1
ratio) and mixed well. This was incubated for 5 minutes at room temperature. The DNAlipid complex (60 μl each) was added to the Vero cells. The cells were then incubated for
2-4 days.

Immunofluorescence Assay of Transfected Vero Cells with p-VAX-WNVprMgE positive
clone (clone 5):
250 μl of methanol/acetone was added to each chamber of cells and incubated for 10
minutes at room temperature. The methanol/acetone was removed and 250 μl of 1% BSA
was added to each chamber and incubated for 30 minutes at room temperature. The
primary antibody (mouse Anti-WNVgE mAb E34, Invitrogen) was diluted in 1% BSA in
a 1:200 ratio and was added to both of the control chambers (200μl/chamber). This was
allowed to incubate at room temperature for 2 hours. The primary antibody was then
removed and the chambers were washed 4 times with 1X PBS. 100 μl of the secondary
antibody (goat - Anti-mouse IgG FITC labeled, Invitrogen) was added to the chambers
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and was allowed to incubate for 2 hours in the dark. The secondary antibody was then
removed and the chambers were washed 4 times with 1X PBS. The slides were then
analyzed using a fluorescent microscope to check for successful expression of the
WNVprMgE antigens in the infected cells.

RESULTS

A midiprep DNA extraction from inoculated E. Coli bacteria (JM109) was
performed in order to maximize the pucIDT-WNVprMgE DNA concentration. The
WNVprMgE was originally cloned into the pucIDT vector, so digestion of the BamH1
restriction sites and separation of the DNA by gel-electrophoresis, which sorts molecules
by molecular weight, is necessary to isolate the gene of interest (WNVprMgE). The DNA
was cut with BamH1 enzyme, and 50 μls (μl) of the digest was run on an agarose gel
(Figure 5). The size of the pucIDT vector is 2.7kb, while the size of the WNVprMgE is
2.1kb. Good separation of the pucIDT and WNVprMgE DNA was not achieved on this
first attempt, but better results were achieved later by optimizing the agarose
concentration of the gel.
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Figure 5 - UV image of digested pucIDT WNVprMgE

The pVAX1 and WNVprMgE DNAs were digested with the enzyme BamH1. Gel
purification is performed in order to minimize possible contamination of both DNAs so
that a successful ligation can be performed. It is also conducted primarily so that the
WNVprMgE gene can be successfully removed from its original vector (pucIDT). Prior
to the gel purification, the pVAX1 DNA was treated with a small amount of Shrimp
Alkaline Phosphatase (rSAP) in order to prevent re-ligation of the vector to itself, which
would prevent insertion of the WNVprMgE gene during the ligation. The gel
electrophoresis was run out at a lower voltage for a longer period of time in order to
create as much separation between the two bands as possible in order to minimize
contamination of the WNVprMgE DNA (third lane of Figure 6). The bottom band in lane
three contains the WNVprMgE DNA and it was excised carefully with a sterile scalpel so
that the purified pVAX1 and purified WNVprMgE DNA could be ligated together. DNA
ligation occurs with the formation of a phosphodiester bond between juxtaposed 5’
phosphate and 3’ hydroxyl termini in the DNAs that are being joined. Essentially, it
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facilitates the joining of the two sets of DNAs together so that they can both be present
within a single plasmid.

3.0kb →

2.1kb

1

2

3

Figure 6 - UV image of Restriction Digest & gel purification of WNVprMgE & pVAX1 DNA

The ligated pVAX1-WNVprMgE DNA was then electroporated into electrocompetent E. Coli NEB5-α cells, which were plated onto LB Amp. plates to grow up
clones. DNA was isolated from the clones at random in order to re-analyze the DNA and
verify that the WNVprMgE DNA is present. WNVprMgE forward and reverse primers
were used to amplify the WNV gene, which would confirm its presence. The PCR
product of clone #1 is observed in the second lane of the gel image of Figure 7, while the
first lane is the molecular marker. The bottom band in lane 2 is approximately 2.1kb,
which is the expected size of the WNVprMgE DNA, indicated its presence. The streaking
observed in the UV image could be due to possible contamination of some of the DNA,
overloading of the lane, or could be due to the fact that this gel was only run for 45
minutes at 100V; a longer run time could possibly produce better, cleaner separation of
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the bands. The important conclusion of this image is confirmation of the fact that the
WNVprMgE DNA was present after PCR, which amplifies the gene that was primed.
MW

pVAXWNVprMgE

2.1kb

2

1

Figure 7 - UV image of PCR product pVAX1-WNVprMgE in NEB5-α cells

The next step to be done is to confirm the correct orientation of the gene. The
results with the original clones were ultimately negative, because even though the insert
DNA was present, it did not clone in the correct orientation where the WNVprMgE gene
ATG start codon is downstream of the CMV promotor. Further clones were randomly
selected and the process was repeated in hopes of finding clones where the insert was
present in the vector in the correct orientation (Figure 8).
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Figure 8 - PCR Orientation

Six more clones were randomly selected from the previous plate, and were
inoculated and incubated overnight, and then DNA was extracted from each using a
Miniprep Kit for analysis. The DNA was digested using BamH1 and the digested product
of clones 5-9 were run on a 0.5% agarose + EtBr gel (Figure 9). All clones were
observed to be positive in the sense that both the pVAX1 vector and WNV insert DNA
were present. A second PCR was then conducted for each of the new clones to confirm if
any had the WNVprMgE gene insert cloned in in the correct orientation.
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Figure 9 - UV image of digested pVAX1-WNVprMgE NEB5-α clones 5-9

The WNV gene’s presence alone is not enough to ensure that it is a potentially
viable vaccine. In order to determine if the gene of interest is being correctly expressed in
the vaccine construct, Polymerase Chain Reaction (PCR) amplification is necessary.
When the gene of interest is ligated into the pVAX1 construct, it can be cloned in in
either the correct or incorrect orientation due purely to chance. To determine if a clone
has the WNV gene in the correct orientation, a forward T7 primer and reverse
WNVprMgE primer were used to determine the orientation of the start and stop codons
of the gene of interest relative to the CMV promotor and Polyadenylation site of the
pVAX1 vector. The CMV promotor is used commonly for general expression and is a
strong mammalian expression promotor isolated from the Human Cytomegalovirus. (24)
The choice of promotor is very important because it needs to be suited to work well
within the host organism, which is why the CMV promotor is used since the host
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organism would be, preferably, a human. It is very important that the gene of interest is
inserted in the correct orientation where the start codon (ATG) is relative to the CMV
promotor so that the successful expression of the WNVprMgE is accomplished. The gene
of interest also needs to be inserted where the 3’ end, the end that is being terminated, is
upstream of the polyadenylation site. Polyadenylation adds a transcription termination at
the 3’ end of the gene being expressed, so it is vital for successful transcription that the
WNV gene is in the orientation where the stop codon is upstream to the polyadenylation
site so that the process of releasing the newly synthesized RNA from the transcription
machinery can begin. Confirmation of the gene of interest’s orientation was analyzed via
PCR using a T7 forward and WNVprMgE reverse primer. Primers enhance both strands
that are of interest, in this case the WNVprMgE strands. The forward primer is for the
beginning of the gene and the reverse primer begins the complimentary strand. By using
both of these primers the gene’s orientation can be determined by observing a 2.1kb band
in the agarose gel, which would indicate that the gene was primed and amplified.
A PCR was conducted using a WNVprMgE reverse primer along with a T7
promotor. PCR products for clones 5, 6, 7, and 8 were analyzed on an agarose gel (Figure
9). Clones 5, 7, and 8 were observed to be positive for correct orientation of the
WNVprMgE insert, indicated by a band being present at 2.1kb, while clone 6 was
negative (Figure 10). Clones 5 and 7 were selected and sent for sequencing for further
confirmation.
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Figure 10 - PCR product of pVAX1-WNVprMgE clones 5-8

A digest of the pVAX1-WNVprMgE NEB5-α clone 5 was conducted for further
confirmation while awaiting sequencing results (Eurofins Genomics). Sequencing data,
when interpreted, can provide absolute confirmation of the presence of the start codon of
the gene of interest relative to the CMV promotor of the plasmid. The UV image can be
observed in Figure 11, with lane one being the molecular marker and lanes two and three
containing the digested material that was divided evenly between the two lanes. The UV
image further confirms the presence of both the insert and vector DNA. (Two lanes were
used because of excess digest, both lanes contain digested pVAX1-WNVprMgE NEB5-α
clone 5 DNA)
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Figure 11 - BamH1 Digest of pVAX1-WNVprMgE NEB5-α Clone #5

Transfection of pVAX1-WNVprMgE into Vero Cells:
Vero cells were seeded onto chamber slides and then transfected with the
pVAX1-WNVprMgE isolated DNA, and confirmation of the successfully expressed
antigens were analyzed via immunofluorescence. Primary and secondary antibodies were
used in this assay (Invitrogen). The primary antibody attaches to the antigen
(WNVprMgE) with its Fab end, and the secondary antibody attaches to the primary
antibody’s Fc end and contains a fluorescent marker for visual confirmation during the
assay on its Fc end. Positive and negative controls were utilized in this study, with the
negative controls receiving no amount of pVAX1-WNVprMgE DNA. All controls were
given the primary and secondary antibody treatment. The chambers were analyzed under
a fluorescent microscope. The fluorescent glow that can be observed in the assay
confirms that the primary antibody was able to find and attach to the antigen, which
means the antigenic proteins were successfully expressed in the Vero cells, indicating
that the vaccine creation was a success. (Figure 12)
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Figure 12 – Immunofluorescence Assay of Transfected Vero Cells

CONCLUSION:
The WNVprMgE gene was successfully cut and isolated from the pucIDT vector
by the digestion of the BamH1 restriction sites. The same restriction sites in the pVAX1
vector were digested, and re-ligation of the vector to itself was prevented by the addition
of rSAP, which cleaves the exposed 5’ and 3’ phosphate ends. Successful T4 DNA
ligation was accomplished by inserting the gene of interest into the pVAX1 vector. After
multiple attempts, correct orientation of the insert was confirmed in select clones via PCR
amplification of the WNV gene using a T7 forward primer and reverse WNVprMgE
primer. Sequencing results (Eurofins Genomics) offered further confirmation that the
gene was inserted in the correct orientation. The pVAX1-WNVprMgE clone 5 DNA was
isolated, and successful transfection of Vero cells was accomplished and observed via an
immunofluorescence assay using primary and secondary antibodies, confirming
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successful WNVprMgE expression, meaning the vaccine was created and that it was
successful in expressing the WNV antigens in the Vero cells. The success of this
experiment is important because we have proven that successful WNV antigen
expression is possible in cells through the use of our vaccine, which could potentially be
utilized as a method of preventing this disease which has killed thousands of people.
The next steps in this study would be to move on to animal trials using
immunized mice; if it showed favorable results in animal trials, it could potentially move
on to human trials. The pVAX1 vector is one of the main DNA vaccine vectors which
has been approved for use in human trials, which is the primary reason it was used in this
study. It is clear that a vaccine against WNV is needed, and I believe we are now a little
closer to that goal.
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CHAPTER III: RECOMBINANT VZV VACCINE CONSTRUCTION

INTRODUCTION:

As stated previously, the Varicella-zoster Virus (VZV) vaccine induces immunity
against childhood chickenpox and shingles disease in older adults. (16) Due to many pros
of the vaccine, the theory is that this vaccine might be altered to form a recombinant
vaccine expressing the antigens of interest of various other diseases. The thought process
behind the possible viable use of this vaccination strategy is due to its widespread use and
safety, as well as the success rate of lifelong protection of those vaccinated against the
Varicella Zoster Virus. The vaccine also replicates in the nucleus of the cell, which
means that the inserted antigens would be spliced and replicated along with the virus in a
very natural way. The purpose of this chapter is to discuss the preliminary methods of
creating a recombinant Varicella Zoster Virus (rVZV) vaccine expressing the
WNVprMgE antigens.

SPECIFIC AIM OF THIS STUDY:

The goal of this experiment is to insert the WNVprMgE into the VZV vaccine
virus genome. The entire VZV genome is cloned into a bacterial artificial chromosome
(BAC). In this project, the WNVprMgE gene was separated from the pucIDT vector and
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successfully ligated into the MCS of the p-fast BAC vector. The CMV promotor, WNV
gene, and polyadenylation site of the p-fast BAC vector were then transposed into the
attachment (att) site of the engineered VZV BAC. Successful transposition resulted in the
lacZ gene of the VZV BAC being disrupted, as determined through blue/white screening
of clones on LB plates treated with Xgal. If white clones appear, then it proves that the
lacZ site has been disrupted and that the WNVprMgE gene was successfully cloned into
the VZV BAC.

PROJECT OVERVIEW:

Figure 13 – Overview of rVZV Vaccine Creation

The first task to accomplish is identical to the creation of the DNA vaccine: the
WNVprMgE DNA must be separated from the pucIDT vector (Figure 13). This is
accomplished by digesting the BamH1 restriction sites, separating the molecules by
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molecular weight via gel-electrophoresis, and excising the separated WNVprMgE DNA
with a sterile scalpel. The first vector that the WNV gene must be cloned into is the p-fast
BAC. The p-fast BAC also contains a BamH1 restriction site in the Multiple Cloning Site
(MCS), which when digested, allows the WNVprMgE gene to be inserted (Figure 13).
The p-fast BAC DNA was treated with 1 μl of Shrimp Alkaline Phosphatase (rSAP) after
it was digested with BamH1 in order to prevent re-ligation to itself. After the
WNVprMgE DNA was successfully cloned in to the p-fast BAC vector, the p-fast BACWNVprMgE DNA was isolated and electroporated into a BAC which contained the
entire Varicella Zoster Virus (VZV) genome. During electroporation, everything between
the Tn7R and Tn7L transposon sites of the p-fast BAC was translocated into the att site
that is present in the VZV BAC, including the CMV promotor, the WNV gene, and the
polyadenylation site (Figure 13). The att site allows insertion of DNA so that it will be
incorporated into its genome and will replicate when the bacteria does. This att site was
engineered to contain a lacZ gene, which will be disrupted when the WNVprMgE DNA
is inserted. This mechanism allows us to conduct blue/white color screening of clones
that are plated on LB plates treated with Xgal. If the WNV gene was successfully inserted
into the att site, the lacZ gene would be disrupted and the clone would appear white on
the plate and successful insertion of the WNV gene into the VZV BAC would have been
accomplished. If the WNV gene was not successfully inserted, the lacZ site would not be
disrupted and the clones appear blue on the plate.
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METHODS:

Overnight digest of p-fast BAC and WNVprMgE with BamH1:
An overnight digest of p-fast BAC and pucIDT-WNVprMgE was set up as follows: (2x)
3 μl of DNA, 1.5 μl of BamH1, 2.5 μl of Buffer 10X, and 18 μl of d2H2O, for a 25-μl
total reaction. The digests were allowed to incubate overnight in a water bath at 37
degrees C. The digests were run on a 0.5% Agarose + EtBr gel at 90V for 2 hours to
create maximum DNA band separation.

Gel purification of p-fast BAC and WNVprMgE digests:
The p-fast BAC and WNVprMgE bands were excised from the 0.5% Agarose + EtBr gel
using a clean scalpel. The DNAs were gel purified using the QIAquick gel extraction kit
and eluted into 60 μl of TE for storage. A 5 μl sample of gel-purified DNA was run on a
0.5% Agarose + EtBr gel as follows: (2x) 5 μl of gel-purified DNA, 5 μl of loading dye,
and 5 μl of d2H2O for a 15-μl total reaction.

T4 Ligation reaction of purified p-fast BAC and WNVprMgE:
1 μl of Shrimp Alkaline Phosphatase (rSAP) was added to the gel purified p-fast BAC in
order to prevent re-ligation to itself, and was allowed to incubate in a water bath for 1
hour at 37 degrees C. The digest was then heat-inactivated at 65 degrees C for 10
minutes. The ligation reaction between the p-fast BAC and WNVprMgE was set up as
follows: 10 μl of WNVprMgE, 7 μl pf p-fast BAC, 1 μl of T4 ligase, and 2 μl of 2X
Buffer. This was allowed to incubate at room temperature for one hour.
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Electroporation of p-fast BAC + WNVprMgE
7 μl of the ligated p-fast BAC-WNVprMgE DNA was electroporated into 53 μl of
electro-competent NEB5-α cells and 5 μl of d2H2O using a 2cm cuvvete. The cells were
allowed to recover in 1ml of LB for 1 hour at 37 degrees C and 200 rotations per minute
(RMP). The cells were then plated onto 3 LB + ampicillin (Amp.) plates and allowed to
incubate over the weekend at 37 degrees C to grow clones. Many clones were picked at
random onto another LB + Amp. plate and grown overnight at 37 degrees C.

Miniprep DNA Extraction of p-fast BAC + WNVprMgE NEB5-α clones:
Four clones were chosen at random and inoculated into 5 ml of LB broth + 10 μl of Amp
and were grown overnight at 37 degrees C and 200 RPM. DNA was extracted from the
clones using the QIAprep Miniprep Kit and eluted into 50 μl of TE for storage.

Overnight BamH1 digest of p-fast BAC + WNVprMgE clones (1-4):
Four overnight digests with BamH1 were set up as follows: (4x) 8 μl of clone DNA, 1.5
μl of BamH1, 2.5 μl of Buffer 10X, and 13 μl of d2H2O. The four digests were allowed
to incubate overnight in a water bath at 37 degrees C and were run on a 0.5% Agarose +
EtBr gel at 100V for one hour the next day. The results were analyzed via UV transillumination. Clones 1 and 3 appeared to be positive for the presence of both the p-fast
BAC and WNVprMgE DNAs and were selected to be analyzed further via PCR.
PCR confirmation of p-fast BAC + WNVprMgE positive clones (clones 1 & 3)
A PCR was set up using the fwd. and rev. primer of the WNVprMgE and was allowed to
run overnight as follows: Clones #1: 1 μl of fwd. WNVprMgE primer, 1 μl of rev.
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WNVprMgE primer, 4 μl of digested DNA, and 44 μl of PCR Super Mix. Clone #3: 1 μl
of fwd. WNVprMgE primer, 1 μl of rev. WNVprMgE primer, 4 μl of digested DNA, and
44 μl of PCR Super Mix. The PCR was carried out as normal protocol, except with a 4minute elongation step. The PCR products were analyzed on a 0.5% Agarose + EtBr gel
at 90V for one hour and analyzed using UV trans-illumination.

PCR reaction of p-fast BAC + WNVprMgE clones (1 & 3) with positive and negative
controls:
A PCR for the positive p-fast BAC-WNVprMgE clones was set up as follows: Clone #1:
1 μl of fwd. WNVprMgE primer, 1 μl of rev. WNVprMgE primer, 4 μl of digested DNA,
and 44 μl of PCR Super Mix. Clone #3: 1 μl of fwd. WNVprMgE primer, 1 μl of rev.
WNVprMgE primer, 4 μl of digested DNA, and 44 μl of PCR Super Mix. Positive
control: 4 μl of pucIDT WNVprMgE DNA, 1 μl of fwd. WNVprMgE primer, 1 μl of rev.
WNVprMgE, and 44 μl of PCR Super Mix. Negative control: 4 μl of p-fast BAC DNA, 1
μl of rev. WNVprMgE primer, 1 μl of fwd. WNVprMgE primer, and 44 μl of PCR Super
Mix. The total reaction volume for each was 50 μl. The PCR was carried out using
normal protocol, except with a 2-minute elongation step. The PCR products were run on
a 0.5% Agarose + EtBr gel at 90V for 1 hour and analyzed using UV trans-illumination
to confirm presence of the primed WNVprMgE gene.

Midiprep and Transposition of WNVprMgE into VZV BAC LacZ
The DNA from clone 3 was extracted and eluted into 200 μl of TE via the Qiagen
Plasmid Midi Kit protocol for storage. (Midiprep concentration = 1550 ng/μl) A BamH1
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digest was set up as follows: 2 μl of DNA, 1.5 μl of BamH1, 2.5 μl of Buffer 10X, and 19
μl of d2H2O for a 25 μl total reaction. This was allowed to incubate overnight in a water
bath at 37 degrees C. The digest were run on a 0.5% Agarose + EtBr gel and analyzed via
UV-trans-illumination for further confirmation of the p-fast BAC and WNVprMgE
presence. The p-fast BAC + WNVprMgE clone 3 was then electroporated into E. coli
containing the VZV BAC + LacZ-att Tn7 (9/20/17) using a 0.1cm cuvette as follows: 50
μl of the BC VZV BAC + LacZ-att. Tn7 NEB5-α clone 4.1, 10 μl of d2H2O, 1.5 μl of
pMON 7124 DNA, and 1 μl of p-fast BAC + WNVprMgE clone 3. This was then resuspended in 1ml of LB and allowed to recover for 2 hours. This process was repeated
using a negative control, which uses d2H2O in place of the DNA. The cells were plated
on LB + CAM/TET/AMP plates for triple antibiotic screening. White clones were then
selected and picked onto a separate plate, and 3 clones were chosen at random and
inoculated into 5ml LB and incubated overnight. These cultures were then combined with
100 μl of LB and allowed to incubate overnight.
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RESULTS

Isolation of WNVprMgE DNA & Digestion of p-fast BAC vector
The WNVprMgE DNA separation from the pucIDT vector was accomplished by
digestion of the BamH1 restriction sites of the pucIDT, separation of the DNAs by
molecular weight via gel electrophoresis, and excision of the WNVprMgE DNA band
with a sterile scalpel. The p-fast BAC DNA was also digested with BamH1 and treated
with a small amount of Shrimp Alkaline Phosphatase (rSAP) to prevent re-ligation of the
vector to itself, which would prevent the WNVprMgE gene from being ligated into the pfast BAC vector.

Gel-purification of the p-fast BAC & WNVprMgE DNAs
The p-fast BAC and WNVprMgE DNAs were gel purified before the ligation in
order to remove any possible contamination. The gel-purified p-fast BAC and
WNVprMgE DNA can be observed in Figure 14 in the second and third lanes,
respectably. This gel purification was done in order to limit the risk of DNA
contamination.
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Figure 14 - BamH1 Digest + gel purification of p-fastBAC & WNVprMgE

p-fast BAC & WNVprMgE Ligation & Electroporation into NEB5- α cells
The p-fast BAC and WNVprMgE DNAs were ligated together using a T4 DNA
ligation protocol. The ligated p-fast BAC-WNVprMgE DNA was electroporated into
electro-competent NEB5- α cells and clones were grown over the weekend against Amp.
selection to help avoid possible contamination.
BamH1 Digest of p-fast BAC-WNVprMgE clones
DNA was isolated from the clones and cut with BamH1, and the digests were
analyzed on the UV image seen in Figure 15, where the first lane contains the molecular
weight marker and lanes 2-5 contain clones 1- 4. Clones 1 and 3 appear to be positive,
meaning they have the presence of both the p-fast BAC and WNVprMgE DNA, and were
further analyzed via PCR.
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Figure 15 - BamH1 Digests of p-fastBAC + WNVprMgE NEB5-α clones 1-4

PCR of p-fast BAC-WNVprMgE with Fwd. and Rev. Primers
Clones 1 and 3 were selected, and four 50 μl reactions were carried out (2
reactions per clone) and amplified via PCR, which can be observed in Figure 16. Every
clone received the p-fast BAC forward primer, while one reaction for each clone received
the WNVprMgE forward primer and the other received the WNVprMgE reverse primer.
Orientation of the WNVprMgE gene was analyzed by sequencing results (Eurofins
Genomics). The ATG start codon of the WNVprMgE gene was found to be downstream
of the CMV promotor of the p-fast BAC vector, inferring correct orientation of the
inserted gene.
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Figure 16 - UV image of PCR product of p-fast BAC + WNVprMgE clones 1 & 3

Four more PCRs were conducted, this time with a two-minute elongation step,
and the results can be observed in Figure 17. All four reactions were run with a forward
and reverse primer for the WNVprMgE. The first lane is the molecular weight solution,
the second lane contains clone 1, the third lane contains clone 3, the fourth lane contains
the positive control, and the fifth lane contains the negative control. The positive control
contained pucIDT WNVprMgE DNA, while the negative control contained p-fast BAC
DNA. Slight banding patterns that match the positive control’s presence of the
WNVprMgE insert can be seen in clones 1 and 3.
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Figure 17 - UV image of PCR reaction of p-fast BAC + WNVprMgE clones 1 & 3 w/ pos. and neg. controls

Electroporation of p-fast BAC into the VZV BAC:
Clone 3 was selected to be electroporated into the VZV BAC + LacZ-attachment
site at Tn7 [NEB5-α clone 4.1 (9/20/2017)]. The bacterial artificial chromosome (BAC)
of the VZV vaccine contains an attachment (att) site at the Lac-Z gene in the Tn7 region,
the goal is to successfully attach the p-fastBAC WNVprMgE to the attachment site, thus
disrupting the LacZ gene. The clones were plated onto LB plates containing Xgal in order
to conduct blue/white screening of the clones to determine if the LacZ gene had been
disrupted. Xgal is a substrate which is designed so that the enzyme created by the LacZ
gene (beta-galactosidase) will convert the Xgal into a blue color. White clones were
selected and picked onto a separate plate, because the absence of the blue coloration
confirmed that the LacZ gene was not converting the Xgal into a blue color, which means
that the LacZ site had been disrupted, thus inferring that the WNV insert had been
successfully cloned into the attachment site.
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CONCLUSION:
In this study, it was shown that it is possible to clone the WNVprMgE gene into a
VZV BAC. The next step of this study would be to successfully transfect Mewo cells
(Human melanoma cells) with the isolated DNA and observe expression of the
WNVprMgE antigens through an immunofluorescence assay using primary and
secondary antibodies. Unfortunately, due to time constraints we were not able to carry
out these next steps, but it is something that will be a focus of Dr. Gray’s lab in the
future. The important take-away of this study is the affirmation that a rVZV vaccine is
potentially a very viable tool for vaccination against WNV and many other diseases
which present a molecular antigen complex.
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CHAPTER IV: A SUMMARY & CONCLUSION

WNV is a disease which still plagues many parts of the world, and it is clear that a
vaccine is necessary. This study attempts to offer a possible solution to different
vaccination methods that could prove to be extremely viable options. The process that has
been started will hopefully push the development of a viable vaccination method that can
be used worldwide. In this study we managed to construct a DNA vaccine and
accomplish successful transfection, and construct a recombinant VZV vaccine, both
expressing the Premembrane and Glycoprotein E antigens of the West Nile Virus. The
transfection of the rVZV vaccine needs additional work, which will be carried out by Dr.
Gray and those who work in his lab in the near future, but the methodology shows very
promising results.
While the vaccines were created, and we proved that the DNA vaccine could
potentially be effective, there is still much more to do in the arena of virology and
medical standards for it to be viably useful clinically. This is due to the fact that although
successful expression of the proteins in animal cells isolated from specific tissues was
demonstrated, we do not know how effective it would be in the human body and the
potential side effects that could be induced in a human system. These vaccines would
need to undergo extensive animal trials and show promising results to even make it to the
human clinical trials stage. Even then, it is known in the scientific world that
approximately less than half of the experiments that make it past animal trials show
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success in clinical trials. (20) Nevertheless, this study has proven its potential for use,
especially since the WNV antigens were successfully cloned into the rVZV vaccine,
which opens up several doors of possibility into a viable vaccination method. Personally,
this study has provided me with ample valuable experience in the world of
microbiological laboratory study and has challenged me more than I imagined it would. I
have gained an astronomical amount of respect for those that conduct the research that is
so vital to the medicinal world. Until now, I could never grasp the immense amount of
work that goes into any and every thing that is used in the medical field. I now truly
understand that any advancement, no matter how big or small, is only made possible
through the hard work and endless hours devoted by research scientists. I am very
grateful for the opportunity to conduct this research and compose this comprehensive
thesis.
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